GHIT Fund is ramping up investments for researchers working on antimalarial and tuberculosis drugs and treatments.
The move highlights the Japanese government's commitment to playing a leading role in global health issues.
This malaria vaccine candidate is given to humans but targets mosquitoes, and clinical trials may commence in as little as four years.
GHIT Fund, a public-private partnership that seeks to nurture Japan's R&D, has invested in a malaria vaccine and rapid field test.
DNDi has formed a consortium with four pharmaceutical companies to hasten the development of drugs for leishmaniasis and Chagas disease.
An additional US$11 million has been committed to developing diagnostics and drugs for neglected tropical diseases.